Back to Search Start Over

Lung cancer organoids, a promising model still with long way to go.

Authors :
Ma HC
Zhu YJ
Zhou R
Yu YY
Xiao ZZ
Zhang HB
Source :
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Mar; Vol. 171, pp. 103610. Date of Electronic Publication: 2022 Jan 31.
Publication Year :
2022

Abstract

Lung cancer organoids (LCOs) have sprung up in more and more researching fields, because of their ability to recapitulate the three-dimensional structure and functions of the in vivo counterpart organs. However, the culture system for LCOs is still immature, resulting in limited success rate and low tumor purity when culturing LCOs. This is mainly due to the deficiency of an optimal formula of culture medium specially for LCOs. Various cytokines and small molecules have been added in the LCOs culturing system. Compound screening, considering both the mechanism of these molecules and the complexity of lung cancer types is warranted to optimize LCOs culture medium. As methods to culture LCOs increase in sophistication, this model will undoubtedly stand its ground in the coming years in every aspect of cancer researches, especially with major advantages in the field of personalized medicine and tumor microenvironment researches.<br /> (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1879-0461
Volume :
171
Database :
MEDLINE
Journal :
Critical reviews in oncology/hematology
Publication Type :
Academic Journal
Accession number :
35114386
Full Text :
https://doi.org/10.1016/j.critrevonc.2022.103610